Stroke; a journal of cerebral circulation
-
Randomized Controlled Trial Multicenter Study
Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial.
NXY-059 is a free radical-trapping neuroprotectant developed for use in acute ischemic stroke. To facilitate prompt administration of treatment, potentially before neuroimaging, we investigated the safety of NXY-059 in patients with intracerebral hemorrhage (ICH). ⋯ NXY-059 given within 6 hours of acute ICH has a good safety and tolerability profile, with no adverse effect on important clinical outcomes.